LETBEV Trademark

Trademark Overview


On Monday, June 16, 2025, a trademark application was filed for LETBEV with the United States Patent and Trademark Office. The USPTO has given the LETBEV trademark a serial number of 99236970. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, December 23, 2025. This trademark is owned by Pfizer Inc.. The LETBEV trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, cachexia, hypertension, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Smoking cessation preparations; Vaccines for human use
letbev

General Information


Serial Number99236970
Word MarkLETBEV
Filing DateMonday, June 16, 2025
Status686 - PUBLISHED FOR OPPOSITION
Status DateTuesday, December 23, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 23, 2025

Trademark Statements


Goods and ServicesPharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, cachexia, hypertension, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Smoking cessation preparations; Vaccines for human use

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, June 16, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10001-2192

Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10001-2192

Trademark Events


Event DateEvent Description
Monday, June 16, 2025APPLICATION FILING RECEIPT MAILED
Monday, June 16, 2025NEW APPLICATION ENTERED
Monday, June 16, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, October 17, 2025TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, October 17, 2025ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, October 17, 2025TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, October 17, 2025TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Wednesday, October 22, 2025ASSIGNED TO EXAMINER
Thursday, October 23, 2025NON-FINAL ACTION WRITTEN
Thursday, October 23, 2025NON-FINAL ACTION E-MAILED
Thursday, October 23, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, November 4, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, November 4, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, November 4, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, November 26, 2025APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 17, 2025NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 23, 2025PUBLISHED FOR OPPOSITION
Tuesday, December 23, 2025OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED